Genmab develops fully human, high affinity antibodies to treat life-threatening and debilitating diseases. Some of our HuMax antibodies have been shown to be 100 to 1000 times better at finding and binding to their disease target than earlier generations of murine or laboratory-engineered antibodies which are not fully human. In addition, we believe that fully human antibody therapies may have other advantages over older generation products, such as a more favorable safety profile and improved treatment regimens.

Three of Genmab's antibodies are currently available for licensing. Click on each product for more information.

Zanolimumab (HuMax-CD4) - oncology

HuMax-IL8 - autoimmune disease and oncology

HuMax-HepC - infectious disease

Genmab's UniBody technology is also available for licensing.

For more information on licensing opportunities at Genmab, please contact our Business Development department at licensing@genmab.com.